According to multiple recent market analyses, the global API market is experiencing steady growth. One comprehensive forecast ...

In the evolving landscape of pharmaceutical development, modified release (MR) tablets have emerged as a cornerstone technology for improving therapeutic outcomes and patient compliance. Unlike ...

India’s largest drug-maker Sun Pharmaceutical Industries posted a 16 per cent year-on-year (Y-o-Y) growth in its consolidated ...

Union Budget 2026 | Investor attention is expected to turn to active pharmaceutical ingredient (API) makers, specialty drug ...

New sublingual delivery system designed to enhance bioavailability and speed of onset for major depressive and ...

Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal ...

The company is eyeing a revenue of Rs 1,000 crore by 2028 and expects its API plant in Navi Mumbai, which was damaged in a fire in 2025, to resume complete operations by March, Nair tells Moneycontrol ...

The report compares India’s non-clinical drug approval framework with regulatory practices in the US, European Union, the UK ...

For more information, please contact Sales@frontagelab.com.

Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, will present new safety and ...

Ardena completes divestment of its Södertälje drug substance site in Sweden to NanologicaGhent, Belgium, 29th January 2026 – Ardena, a specialist CDMO and bioanalytical CRO enabling precision ...

Poorly soluble molecules face unique challenges that can slow development and limit clinical success. Early formulation decisions are critical for determining bioavailability, in vivo exposure and the ...